Works matching IS 23744677 AND DT 2022 AND VI 8 AND IP 1
Results: 133
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00439-5
- By:
- Publication type:
- Article
GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00438-6
- By:
- Publication type:
- Article
Allelic expression imbalance of PIK3CA mutations is frequent in breast cancer and prognostically significant.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00435-9
- By:
- Publication type:
- Article
Management of the axilla in T1-2N1 breast cancer.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00432-y
- By:
- Publication type:
- Article
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00430-0
- By:
- Publication type:
- Article
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00434-w
- By:
- Publication type:
- Article
Author Correction: Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2/N0 HER2+ breast cancer.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00433-x
- By:
- Publication type:
- Article
A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00429-7
- By:
- Publication type:
- Article
Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00427-9
- By:
- Publication type:
- Article
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00426-w
- By:
- Publication type:
- Article
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00423-z
- By:
- Publication type:
- Article
Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00428-8
- By:
- Publication type:
- Article
Lipid exposure activates gene expression changes associated with estrogen receptor negative breast cancer.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00422-0
- By:
- Publication type:
- Article
Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00425-x
- By:
- Publication type:
- Article
Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00424-y
- By:
- Publication type:
- Article
Is conservative management of ductal carcinoma in situ risky?
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00420-2
- By:
- Publication type:
- Article
Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00416-y
- By:
- Publication type:
- Article
Clinical relevance of pathogenic germline variants in mismatch repair genes in Chinese breast cancer patients.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00417-x
- By:
- Publication type:
- Article
Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00414-0
- By:
- Publication type:
- Article
Publisher Correction: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00415-z
- By:
- Publication type:
- Article
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00406-0
- By:
- Publication type:
- Article
LINC00355 regulates p27<sup>KIP</sup> expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00412-2
- By:
- Publication type:
- Article
The impact of reproductive factors on DNA methylation-based telomere length in healthy breast tissue.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00410-4
- By:
- Publication type:
- Article
PARP inhibition in breast cancer: progress made and future hopes.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00411-3
- By:
- Publication type:
- Article
Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00407-z
- By:
- Publication type:
- Article
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00404-2
- By:
- Publication type:
- Article
Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00413-1
- By:
- Publication type:
- Article
Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00405-1
- By:
- Publication type:
- Article
Gene signatures in patients with early breast cancer and relapse despite pathologic complete response.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00403-3
- By:
- Publication type:
- Article
Sulforaphane suppresses metastasis of triple-negative breast cancer cells by targeting the RAF/MEK/ERK pathway.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00402-4
- By:
- Publication type:
- Article
Intratumoral in vivo staging of breast cancer by multi-tracer PET and advanced analysis.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00398-x
- By:
- Publication type:
- Article
UACA locus is associated with breast cancer chemoresistance and survival.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00401-5
- By:
- Publication type:
- Article
Do current family history-based genetic testing guidelines contribute to breast cancer health inequities?
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00391-4
- By:
- Publication type:
- Article
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00380-7
- By:
- Publication type:
- Article
A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00400-6
- By:
- Publication type:
- Article
A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00399-w
- By:
- Publication type:
- Article
Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Author Correction: Plasma extracellular vesicle long RNA profiles in the diagnosis and prediction of treatment response for breast cancer.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00393-2
- By:
- Publication type:
- Article
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00397-y
- By:
- Publication type:
- Article
Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-6.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-021-00371-0
- By:
- Publication type:
- Article
Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00390-5
- By:
- Publication type:
- Article
Immunotherapy for early triple negative breast cancer: research agenda for the next decade.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00386-1
- By:
- Publication type:
- Article
The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00394-1
- By:
- Publication type:
- Article
Immunoarchitectural patterns as potential prognostic factors for invasive ductal breast cancer.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00389-y
- By:
- Publication type:
- Article
De-escalation in breast cancer surgery.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00383-4
- By:
- Publication type:
- Article
Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00396-z
- By:
- Publication type:
- Article
Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00395-0
- By:
- Publication type:
- Article